Renova Therapeutics Awarded Additional NIH Funding to Continue Paracrine Gene Therapy Research

Renova™ Therapeutics was awarded a $802,500 grant to support the company’s continued preclinical gene therapy research for congestive heart failure (CHF). This is the first portion of a second NIH grant, totaling $1.6 million.
According to the company:

The NIH grant – part of a phase II grant in a three-phase funding structure – was awarded through the agency’s Small Business Technology Transfer program. The grant helps fund the continued research of Renova Therapeutics and its scientific team headed by co-founder H. Kirk Hammond, MD, whose paracrine gene therapy approach has been shown to dramatically improve animal models of congestive heart failure and type 2 diabetes.

Jack W. Reich, Ph.D., CEO and Co-Founder of Renova Therapeutics commented:

With this support from the NIH, we’ve been able to make tremendous progress in the cardiovascular gene therapy field. What we’re working on is a true innovation for a large patient population that has seen only incremental improvements in medicines, resulting in small changes in outcomes. With paracrine gene therapy, we’re talking about the potential to attenuate the debilitating effects of heart failure with a simple IV injection, a common procedure that can be administered in any doctor’s office.

Click here to view the full press release.